<DOC>
	<DOCNO>NCT00017498</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness gemcitabine treat patient recurrent metastatic adenoid cystic cancer head neck .</brief_summary>
	<brief_title>Gemcitabine Treating Patients With Recurrent Metastatic Adenoid Cystic Cancer Head Neck</brief_title>
	<detailed_description>OBJECTIVES : - Assess therapeutic activity gemcitabine , term objective response duration response , patient recurrent metastatic adenoid cystic carcinoma head neck . - Determine acute toxicity drug patient . OUTLINE : This multicenter study . Patients receive gemcitabine IV 30-60 minute day 1 8 . Treatment repeat every 21 day maximum 12 course absence disease progression unacceptable toxicity . Patients follow every 12 week disease progression every 6 month thereafter . PROJECTED ACCRUAL : A total 16-29 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Adenoid Cystic</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic recurrent adenoid cystic carcinoma head neck curative option exist Symptomatic and/or progressive disease At least 1 unidimensionally measurable lesion At least 20 mm conventional technique OR At least 10 mm spiral CT scan No bone metastases lesion Prior radiotherapy target lesion allow progress reappear radiotherapy No CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Bilirubin great 1.25 time upper limit normal ( ULN ) ( 2.5 time ULN liver metastasis present ) AST ALT less 3 time ULN ( 5 time ULN liver metastasis present ) Renal : Creatinine great 1.7 mg/dL Other : No uncontrolled infection No concurrent serious systemic disorder would preclude study No prior concurrent malignancy except : Adequately treat carcinoma situ cervix Basal cell squamous cell skin cancer Any malignancy occur 5 year ago symptoms sign recurrence ( except malignant melanoma , hypernephroma , breast carcinoma ) No psychological , familial , sociological , geographical condition would preclude study compliance Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : No concurrent antiestrogen therapy Concurrent steroid replacement steroid antiemetic allow Radiotherapy : See Disease Characteristics At least 3 month since prior radiotherapy except palliative radiotherapy bone lesions No concurrent radiotherapy Surgery : Not specify Other : At least 1 month since prior investigational agent No concurrent experimental medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage IV salivary gland cancer</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>salivary gland adenoid cystic carcinoma</keyword>
	<keyword>stage IV adenoid cystic carcinoma oral cavity</keyword>
	<keyword>recurrent adenoid cystic carcinoma oral cavity</keyword>
</DOC>